MedMira Receives 2nd Order From Caribbean Distributor Adds MiraWell3(TM) Triple Test to Product Portfolio HALIFAX, Oct. 14 /PRNewswire-FirstCall/ -- MedMira Inc. ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics, announced today that it has received a second order from its Caribbean distributor, Caribbean Medical Inc. (CMI). This most recent order, for MedMira's MiraWell3(TM) Rapid (HBV/HIV/HCV) Triple Tests, follows CMI's September 2004 order for MedMira's MiraWell(TM) Rapid HIV Test. CMI is now distributing two of MedMira's leading products, which are destined for use in hospitals and medical clinics throughout the Caribbean. "MedMira's Triple Test is the only rapid test available in the global market today that can simultaneously detect HIV and hepatitis B and C viruses in just three minutes," says Giles Crouch, vice president marketing and business development for MedMira. "We are encouraged by the almost immediate reorder of CMI and strongly believe that the addition of our Triple Test to its product line-up will result in increasing sales activity. Incidents of co-infection with hepatitis B and/or C can occur with HIV, especially in tropical regions. Recent statistics estimate that 40 per cent of HIV infected individuals in the Caribbean are unaware of their co-infection status," Crouch continued. CMI is based in Curacao in the Caribbean and is headed by Dr. Michael Hermeljin, a respected island doctor. Of the 36 million people occupying the Caribbean region, the United Nations (UN) estimates approximately 2.3 per cent of the population aged 15-49 is infected with HIV; the largest HIV-infected population in the world outside of Africa. The 2004 Report on the Global AIDS Epidemic estimates that some 49 per cent of those infected with HIV were women, a number that is continually increasing. HIV has spread rapidly in this region and has been attributed to early sexual activity and intravenous drug (IVD) use in areas of the Caribbean. More information on CMI can be found at http://www.caribbeanmedical.com/ About MedMira MedMira is a leading global manufacturer and marketer of in vitro rapid diagnostic tests for the clinical laboratory market. MedMira's tests issue reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV, hepatitis B and hepatitis C. The United States Food and Drug Administration (FDA) and the State Food and Drug Administration (SFDA), in the People's Republic of China, have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. MedMira has the only rapid diagnostic device to receive these three prominent government approvals. For more details visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. The Reveal(TM) G2 Rapid HIV-1 Antibody Test is the number one test used in US hospitals according to a CDC study. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing are located in Halifax, Nova Scotia, Canada. This news release contains forward-looking statements, which involves risks and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: MedMira Contact: Dr. James Smith: (902) 450-1588 or e-mail:

Copyright